SC
SLNO

Stempoint Capital’s Soleno Therapeutics SLNO Stock Holding History

Stempoint Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,155
Closed -$797K – 77
2025
Q1 		$797K Buy
+11,155
New +$543K 0.25% 46
2024
Q4 		– Sell
-123,177
Closed -$6.22M – 73
2024
Q3 		$6.22M Buy
+123,177
New +$5.9M 1.86% 17
2024
Q2 		– Sell
-115,833
Closed -$4.96M – 67
2024
Q1 		$4.96M Buy
+115,833
New +$5.24M 1.31% 22

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Stempoint Capital's SLNO Position: Q2 2025 in Review

Stempoint Capital sold out of Soleno Therapeutics (SLNO) in Q2 2025, closing a stake of 11,155 shares — an estimated $797K sold.

Stempoint Capital first reported a position in SLNO in Q1 2024 and held it in 3 quarters. The position peaked at $6.22M in Q3 2024. 233 funds tracked by Wall St. Rank hold SLNO as of Q2 2025.

  • Stempoint Capital reported no remaining Soleno Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stempoint Capital sold 11,155 Soleno Therapeutics shares in Q2 2025, an estimated $797K.
  • Stempoint Capital first reported a position in Soleno Therapeutics in Q1 2024 and held it in 3 quarters.
  • Stempoint Capital's Soleno Therapeutics position peaked at $6.22M in Q3 2024.
  • 233 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2025.

Based on Stempoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.